-
1
-
-
33144460273
-
Menopause and beyond
-
Barker LR, Burton JR, Zieve PD, eds. Philadelphia: Lippincott, Williams & Wilkins
-
Miller RG. Menopause and beyond. In: Barker LR, Burton JR, Zieve PD, eds. Principles of ambulatory medicine. 6th ed. Philadelphia: Lippincott, Williams & Wilkins, 2003.
-
(2003)
Principles of Ambulatory Medicine. 6th Ed.
-
-
Miller, R.G.1
-
3
-
-
0037125379
-
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
-
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
-
(2002)
JAMA
, vol.288
, pp. 321-333
-
-
Rossouw, J.E.1
Anderson, G.L.2
Prentice, R.L.3
-
4
-
-
0034676813
-
Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial
-
Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-63.
-
(2000)
Lancet
, vol.356
, pp. 2059-2063
-
-
Loprinzi, C.L.1
Kugler, J.W.2
Sloan, J.A.3
-
5
-
-
0031859788
-
Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors
-
Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16:237-81.
-
(1998)
J Clin Oncol
, vol.16
, pp. 237-281
-
-
Loprinzi, C.L.1
Pisansky, T.M.2
Fonseca, R.3
-
6
-
-
0036365314
-
Venlafaxine for the control of hot flashes: Results of a longitudinal continuation study
-
Barton D, LaVasseur B, Loprinzi C, Novotny P, Wilwerding MB, Sloan J. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 2002;29:33-40.
-
(2002)
Oncol Nurs Forum
, vol.29
, pp. 33-40
-
-
Barton, D.1
Lavasseur, B.2
Loprinzi, C.3
Novotny, P.4
Wilwerding, M.B.5
Sloan, J.6
-
7
-
-
33144476511
-
-
Trivestin ingredients, www.4jointhealth.com/trivestin.html (accessed 2006 Jan 11).
-
Trivestin Ingredients
-
-
-
8
-
-
0019799332
-
A method for estimating the probability of adverse drug reactions
-
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
-
(1981)
Clin Pharmacol Ther
, vol.30
, pp. 239-245
-
-
Naranjo, C.A.1
Busto, U.2
Sellers, E.M.3
-
9
-
-
33144486562
-
Package insert
-
Philadelphia: Wyeth Pharmaceuticals, November
-
Package insert. Effexor XR (venlafaxine). Philadelphia: Wyeth Pharmaceuticals, November 2003.
-
(2003)
Effexor XR (Venlafaxine)
-
-
-
10
-
-
0041342015
-
Drug-induced hepatotoxicity
-
Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-85.
-
(2003)
N Engl J Med
, vol.349
, pp. 474-485
-
-
Lee, W.M.1
-
11
-
-
0029887138
-
The safety and tolerability of venlafaxine hydrochloride: Analysis of the clinical trials database
-
Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16(suppl):54S-61S.
-
(1996)
J Clin Psychopharmacol
, vol.16
, Issue.SUPPL.
-
-
Rudolph, R.L.1
Derivan, A.T.2
-
12
-
-
0038740699
-
Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: Data from the World Health Organization (WHO) database of adverse drug reactions
-
Spigset O, Hagg S, Bate A. Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int Clin Psychopharmacol 2003;18:157-61.
-
(2003)
Int Clin Psychopharmacol
, vol.18
, pp. 157-161
-
-
Spigset, O.1
Hagg, S.2
Bate, A.3
-
13
-
-
0032847231
-
Influence of CYP2D6 activity on the disposition of the antidepressant agent venlafaxine in humans
-
Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999;9:435-43.
-
(1999)
Pharmacogenetics
, vol.9
, pp. 435-443
-
-
Lessard, E.1
Yessine, M.A.2
Hamelin, B.A.3
O'Hara, G.4
LeBlanc, J.5
Turgeon, J.6
-
14
-
-
0036086164
-
Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone
-
Kohnke MD, Griese EU, Stosser D, Gaertner I, Barth G. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 2002;35:116-8.
-
(2002)
Pharmacopsychiatry
, vol.35
, pp. 116-118
-
-
Kohnke, M.D.1
Griese, E.U.2
Stosser, D.3
Gaertner, I.4
Barth, G.5
-
15
-
-
1642580645
-
Low-dose venlafaxine-associated liver toxicity in chronic hepatitis
-
Epub 23 Dec 2003. DOI 10.1345/aph.1D205
-
Sencan I, Sahin I, Ozcetin A. Low-dose venlafaxine-associated liver toxicity in chronic hepatitis (letter). Ann Pharmacother 2004;38:352-3. Epub 23 Dec 2003. DOI 10.1345/aph.1D205
-
(2004)
Ann Pharmacother
, vol.38
, pp. 352-353
-
-
Sencan, I.1
Sahin, I.2
Ozcetin, A.3
-
16
-
-
0032895772
-
Acute liver damage possibly related to sertraline and venlafaxine ingestion
-
DOI 10.1345/aph.18155
-
Kim KY, Hwang W, Narendran R. Acute liver damage possibly related to sertraline and venlafaxine ingestion (letter). Ann Pharmacother 1999;33:381-2. DOI 10.1345/aph.18155
-
(1999)
Ann Pharmacother
, vol.33
, pp. 381-382
-
-
Kim, K.Y.1
Hwang, W.2
Narendran, R.3
-
19
-
-
13744249191
-
Venlafaxine induced hepatitis
-
Pradeep RJ, Victor G, Iby N, Kurpad SS, Galgali RB, Srinivasan K. Venlafaxine induced hepatitis (letter). J Assoc Physicians India 2004;52:340.
-
(2004)
J Assoc Physicians India
, vol.52
, pp. 340
-
-
Pradeep, R.J.1
Victor, G.2
Iby, N.3
Kurpad, S.S.4
Galgali, R.B.5
Srinivasan, K.6
|